FMP
Kairos Pharma, Ltd.
KAPA
AMEX
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.
1.57 USD
-0.12 (-7.64%)
About
ceo
Dr. John S. Yu M.D., Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://kairospharma.comexchange
AMEX
Description
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.
CIK
N/A
ISIN
US48301N1046
CUSIP
N/A
Address
2355 Westwood Blvd.
Phone
310-948-2356
Country
US
Employee
N/A
IPO Date
Sep 16, 2024
Key Executives
